Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Concomitant Bivalent COVID-19 and Influenza Vaccines
NCT05970887Phase 4Completed
- Sponsor
- Catholic Kwandong University
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran + riltozinameran, quadrivalent influenza vaccine in coronavirus disease 2019 (COVID-19), influenza, sponsored by Catholic Kwandong University. Started Oct 2022; status: completed.
02
Drugs
tozinameran + riltozinameranquadrivalent influenza vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05970887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970887.